A prospective, randomized, double-blinded, split-face/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab-induced acneiform rash - 12/08/17
Funding sources: Supported by Bristol-Myers Squibb (SK2013-0496) and the National Institutes of Health (P30 CA008748/CA/NCI). |
|
Conflicts of interest: Dr Belum is supported by the “RJR” Oncodermatology Fund at Memorial Sloan Kettering Cancer Center. Dr Marchetti reports that he has served as a consultant to Ignyta. Dr Kemeny receives research funding from Amgen. Dr Cercek serves as an advisor to Bayer, Sandoz, and Amgen. Dr Lacouture is supported by the RJR Oncodermatology fund at Memorial Sloan Kettering Cancer Center, and reports that he is serving as a consultant to Quintiles, Boehringer Ingelheim, Genentech, Foamix, Infinity Pharmaceuticals, Janssen R&D, Novartis, and AstraZeneca pharmaceuticals. He has received research funding from Bristol-Myers Squibb, and Berg. Dr Dusza has nothing to disclose. |
|
Previously presented: The background and study methods were presented as a poster at the American Society of Clinical Oncology in Chicago, Illinois, May 30, 2015. |
Vol 77 - N° 3
P. 577-579 - septembre 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?